This has several important implications for manufacturers: Early launch benchmarks may understate success if they focus primarily on switching behavior rather than new-to-therapy initiation The addressable market for oral GLP-1s may be larger than previously modeled , particularly if similar barriers exist across obesity and cardiometabolic indications Pipeline assets following oral semaglutide may enter a more receptive market , where the viability of oral administration has already been established What Great Looks Like: Speed and Clinical Depth at Launch Imagine if, within weeks of launch, pharma leaders could understand the earliest signals of launch performanceincluding prescription activity, patient flow, site of care, and early access dynamicsby assessing near-real-time, large-scale claims and EMR data
Better Lemon Bottle Fat Disssolving Get rid of fat in targeted areas FAST
Understanding the Master Antioxidant Before we look at combinations, we must understand what glutathione actually does
This has led to Lilly investing heavily to support its diabetes and obesity products
This technique demonstrated a high level of diagnostic accuracy (AUC 0.93 for PMCA and 0.89 for RT-QuIC) (Kang et al., 2019), along with an extremely high sensitivity (95.3%) and specificity (98%) (Rossi et al., 2020)
